专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20190194767A1 DETECTION OF DNA SEQUENCES AS RISK FACTORS FOR HIV INFECTION 审中-公开
公开(公告)号：US20190194767A1
公开(公告)日：2019-06-27
申请号：US16299107
申请日：2019-03-11
申请人： Luc Montagnier
发明人： Luc Montagnier
IPC分类号： C12Q1/70 , A61K31/7052 , C12N1/20 , A61K31/65 , C12Q1/689
CPC分类号： A61K31/65 , A61K31/7052 , C12N1/20 , C12N15/11 , C12Q1/689 , C12Q1/703 , Y02A50/402
摘要： A method for identifying a risk factor for diseases, disorders or conditions, such as those caused by human immunodeficiency virus, using the polymerase chain reaction and specific primers. Methods for treating patients having these diseases, disorders or conditions by antimicrobial treatment of the risk factor by combined antiviral and antibacterial treatment or by sustaining or stimulating the subject's immune system. Methods for screening biological products including red blood cell preparations. Primers and methods for detecting nucleic acids or microbial agents associated with red blood cells, such as those associated with red blood cells in subjects infected with HIV and undergoing antiretroviral therapy.

2. 发明申请

US20180147213A1 METHODS OF COSMETICALLY TREATING SKIN CONDITIONS WITH A COSMETIC PERSONAL CLEANSING COMPOSITION 审中-公开
公开(公告)号：US20180147213A1
公开(公告)日：2018-05-31
申请号：US15878537
申请日：2018-01-24
申请人： The Procter & Gamble Company
发明人： Karl Shiqing Wei , Jason Edward Cook , Kevin John Mills
IPC分类号： A61K31/555 , A61Q19/10 , A61Q19/00 , A61K47/06 , A61K8/27 , A61K47/36 , A61K47/14 , A61K8/03 , A61K8/81 , A61K8/49 , A61K8/46 , A61K8/44 , A61K8/31
CPC分类号： A61K31/555 , A61K8/03 , A61K8/27 , A61K8/31 , A61K8/44 , A61K8/466 , A61K8/4933 , A61K8/8152 , A61K47/06 , A61K47/14 , A61K47/36 , A61K2800/548 , A61K2800/58 , A61Q19/007 , A61Q19/10 , Y02A50/401 , Y02A50/402 , Y02A50/406
摘要： A method of treating a skin condition including applying a rinse-off multi-phase cleansing composition including a cleansing phase including an anionic surfactant and zinc pyrithione and a benefit phase including a benefit agent.

3. 发明申请

US20170283477A1 ANIMAL MODEL OF LONGEVITY AND RELATED METHODS FOR INCREASING LONGEVITY AND INHIBITING TUMORIGENESIS 审中-公开
公开(公告)号：US20170283477A1
公开(公告)日：2017-10-05
申请号：US15507650
申请日：2015-09-01
申请人： ACADEMIA SINICA
发明人： Che-Kun James SHEN , Yu-Chiau SHYU
IPC分类号： C07K14/47 , A61K38/17 , A61K45/06 , A01K67/027
CPC分类号： C07K14/4702 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0331 , A61K38/1709 , A61K45/06 , C07K14/4703 , Y02A50/402
摘要： The present invention includes a genetically-modified non-human animal model of longevity and increased health span, which is associated with reduced tumorigenesis and tumor metastasis, as well as related methods for increasing longevity and health span, reducing tumorigenesis and tumor metastasis, and identifying active agents that confer increased longevity or health span, or reduced tumorigenesis or tumor metastasis.

4. 发明申请

US20170232060A9 ANTIMICROBIAL 4-OXOQUINOLIZINES 审中-公开
公开(公告)号：US20170232060A9
公开(公告)日：2017-08-17
申请号：US15191067
申请日：2016-06-23
申请人： Emergent Product Development Gaithersburg Inc.
发明人： Jutta HEIM , Peter SCHNEIDER , Patrick ROUSSEL , Daniel MILLIGAN , Christian BARTELS , Glenn DALE
IPC分类号： A61K38/12 , A61K31/444 , A61K31/506 , A61K31/4375
CPC分类号： A61K38/12 , A61K31/4375 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/496 , A61K31/506 , C07D455/02 , Y02A50/402 , Y02A50/475 , Y02A50/478 , Y02A50/479 , Y02A50/481 , A61K2300/00
摘要： This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

5. 发明申请

US20170202975A1 DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL-BINDING MOLECULE 审中-公开
公开(公告)号：US20170202975A1
公开(公告)日：2017-07-20
申请号：US15479903
申请日：2017-04-05
申请人： Suzhou M-Conj Biotech Co., Ltd.
发明人： Robert Yongxin ZHAO
IPC分类号： A61K47/48 , A61K31/5365 , C07K19/00
CPC分类号： A61K31/337 , A61K31/404 , A61K31/5365 , A61K31/551 , A61K31/5513 , A61K45/06 , A61K47/6803 , A61K47/6889 , A61K49/0002 , C07C243/28 , C07C275/50 , C07C311/55 , C07D207/452 , C07D213/71 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D493/08 , C07D498/14 , C07D519/00 , C07K5/06078 , C07K5/06139 , Y02A50/385 , Y02A50/402 , Y02A50/414 , Y02A50/415 , Y02A50/463 , Y02A50/473 , Y02A50/49
摘要： The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.

6. 发明授权

US09707248B2 Use of thiopyrimidinecarboxamide for treating cancer 有权
公开(公告)号：US09707248B2
公开(公告)日：2017-07-18
申请号：US15279361
申请日：2016-09-28
申请人： Syntrix Biosystems Inc.
发明人： John A. Zebala , Dean Y. Maeda , Aaron D. Schuler
IPC分类号： A61K45/06 , A61K31/69 , C07F5/02 , A61K9/00
CPC分类号： A61K31/69 , A61K9/0053 , A61K45/06 , C07F5/025 , Y02A50/402 , Y02A50/411 , A61K2300/00
摘要： There is disclosed is a method of treating cancer using compound having formula SX-682 alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, VEGF receptor kinase inhibitors, antibodies against the VEGF receptor, interferon, or radiation.

7. 发明申请

US20170196914A1 COMPOSITIONS AND METHODS 有权
公开(公告)号：US20170196914A1
公开(公告)日：2017-07-13
申请号：US15415745
申请日：2017-01-25
申请人： SERES THERAPEUTICS, INC.
发明人： Gregory McKenzie , Mary-Jane Lombardo McKenzie , David N. Cook , Marin Vulic , Geoffrey von Maltzahn , Brian Goodman , John Grant Aunins , Matthew R. Henn , David Arthur Berry , Jonathan Winkler
IPC分类号： A61K35/742 , A61K45/06 , A61K9/00 , A61K9/48 , A61K35/37
CPC分类号： A61K35/741 , A61K9/0053 , A61K9/48 , A61K9/4816 , A61K35/37 , A61K35/74 , A61K35/742 , A61K35/744 , A61K35/745 , A61K35/747 , A61K45/06 , C12N1/20 , Y02A50/402 , Y02A50/469 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/48 , Y02A50/481
摘要： Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.

8. 发明授权

US09597361B2 Treating a bacterial skin infection with a whole, leech saliva extract 有权
公开(公告)号：US09597361B2
公开(公告)日：2017-03-21
申请号：US15223352
申请日：2016-07-29
申请人： Biopep Solutions, Inc.
发明人： Abbas Mohammad Ghawi , Ahmed Merzouk , Abdualrahman Abdualkader , Mohamed Alaama
IPC分类号： A61K35/37 , A61K38/00 , A61K35/62 , A61K9/00 , A01K67/033
CPC分类号： A61K35/62 , A01K67/033 , A01N63/00 , A61K9/0014 , A61K31/282 , A61K31/4745 , A61K31/555 , A61K38/21 , A61K45/06 , Y02A50/385 , Y02A50/387 , Y02A50/393 , Y02A50/40 , Y02A50/401 , Y02A50/402 , Y02A50/406 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/419 , Y02A50/422 , Y02A50/423 , Y02A50/463 , Y02A50/465 , Y02A50/467 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/473 , Y02A50/479 , Y02A50/481 , Y02A50/483 , Y02A50/491 , A61K2300/00
摘要： Methods are also provided for isolating and using a whole-saliva leech extract in the treatment of a bacterial skin infection. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° C.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech. The methods can include revitalizing the leech by warming it at a temperature ranging from about 5° C. to about 40° C. Stable, lyophilized, whole-saliva extracts of a leech are also provided, the extract having a stable activity when stored for use at a temperature below about −20° C., the extract maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treat liquid tumors, treat diabetes, treat a viral disease, treat a parasitic disease, treat an antibacterial disease, or serve as an anti-oxidant.

9. 发明授权

US09585897B2 Anti-infective hydroxy-phenyl-benzoates and methods of use 有权
标题翻译：抗感染性羟基苯基苯甲酸酯及其使用方法
公开(公告)号：US09585897B2
公开(公告)日：2017-03-07
申请号：US14930512
申请日：2015-11-02
申请人： Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
发明人： Michael R. Yeaman , Arnold S. Bayer
IPC分类号： A61K31/60 , A61K38/14 , A61P31/04 , A61K31/603 , A61K31/5377
CPC分类号： A61K31/60 , A61K31/5377 , A61K31/603 , A61K38/14 , Y02A50/402 , Y02A50/47 , Y02A50/473 , Y02A50/481 , Y02A50/483
摘要： The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analog. The extracellular microorganism can be of the bacterial genus Staphylococcus, for example, Staphylococcus aureus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA). The invention also provides a method for preventing or treating an infectious disease caused by of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) or vancomycin-resistant Staphylococcus aureus (VRSA), comprising systemically co-administering in a synergistic combination to a subject in need thereof prophylactically or therapeutically effective amounts, individually or collectively, of a salicylic acid (SAL) or a SAL analog and at least one additional antimicrobial agent, for example, vancomycin and/or linezolid.
摘要翻译：本发明提供了一种预防或治疗由细胞外微生物引起的疾病的方法，所述方法包括向有需要的受试者全身施用预防或治疗有效量的水杨酸（SAL）或SAL类似物。细胞外微生物可以是细菌属葡萄球菌，例如金黄色葡萄球菌。细胞外微生物可以是对至少一种抗生素具有抗性的菌株。该菌株可以选自耐甲氧西林金黄色葡萄球菌（MRSA），万古霉素 - 中间体金黄色葡萄球菌（VISA）和耐万古霉素金黄色葡萄球菌（VRSA）。本发明还提供一种预防或治疗由耐甲氧西林金黄色葡萄球菌（MRSA），万古霉素中间体金黄色葡萄球菌（VISA）或万古霉素耐药金黄色葡萄球菌（VRSA）引起的感染性疾病的方法，其包括全身共同施用于对需要其的预防或治疗有效量的水杨酸（SAL）或SAL类似物和至少一种另外的抗微生物剂例如万古霉素和/或利奈唑胺的预防或治疗有效量的协同组合。

10. 发明申请

US20170058002A1 GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY 审中-公开
公开(公告)号：US20170058002A1
公开(公告)日：2017-03-02
申请号：US15292162
申请日：2016-10-13
申请人： JIANFENG CAI , YOUHONG NIU , HAIFAN WU , SHRUTI PADHEE
发明人： JIANFENG CAI , YOUHONG NIU , HAIFAN WU , SHRUTI PADHEE
IPC分类号： C07K7/56 , A61K47/48 , C07K1/10 , C07K7/06 , C07K1/16
CPC分类号： C07K7/56 , A61K38/00 , A61K38/08 , A61K38/12 , A61K45/06 , A61K47/543 , A61K49/0056 , C07K1/10 , C07K1/16 , C07K7/06 , C07K7/64 , G01N33/569 , Y02A50/40 , Y02A50/401 , Y02A50/402 , Y02A50/411 , Y02A50/469 , Y02A50/471 , Y02A50/473 , Y02A50/478 , Y02A50/479 , Y02A50/483 , Y02A50/52 , Y02A50/56 , Y02A50/59
摘要： The present invention is directed to a novel class of antimicrobial agents called γ-AApeptides. The current invention provides various categories of γ-AApeptides, for example, linear γ-AApeptides, cyclic γ-AApeptides, and lipidated γ-AApeptides. γ-AApeptides of the current invention are designed to exert antimicrobial activity while being stable and non-toxic. γ-AApeptides also do not appear to lead to the development of microbial resistance in treated microorganisms. Thus, the disclosed γ-AApeptides can be used for the treatment of various medical conditions associated with pathogenic microorganisms.
摘要翻译：本发明涉及一种称为γ-AA肽的新型抗微生物剂。本发明提供各种类型的γ-AA肽，例如线性γ-AA肽，环状γ-AA肽和脂质化的γ-AA肽。本发明的γ-AA肽被设计成在稳定和无毒的同时发挥抗菌活性。 γ-AA肽也似乎不会导致处理微生物中微生物抗性的发展。因此，所公开的γ-AA肽可用于治疗与病原微生物相关的各种医学病症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式